Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 17/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | BRD2 | P25440 | 4/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18172285 | 0.85 | BRD4 (0.49) | ATAD2BRD4LMNAALDH1A1CYP1A2 | |
| SCHEMBL20061675 | 0.82 | ERN1 (0.48) | BRD4LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19726803 | 0.79 | BRD4 (0.51) | ATAD2BRD4LMNAALDH1A1CYP1A2 | |
| SCHEMBL15836986 | 0.74 | BRD4 (0.54) | ATAD2BRD4BRD2CREBBP | |
| SCHEMBL19231225 | 0.74 | BRD4 (0.50) | ATAD2BRD4BRD2 | |
| SCHEMBL18172284 | 0.73 | CYP1A2 (0.62) | BRD4LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL18172283 | 0.73 | CYP1A2 (0.48) | BRD4LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL17807840 | 0.73 | BRD4 (0.52) | ATAD2BRD4CYP1A2BRD2CREBBP | |
| SCHEMBL20832798 | 0.73 | CYP1A2 (0.49) | BRD4LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL16861736 | 0.71 | BRD4 (0.50) | ATAD2BRD4BRD2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | EP300, HDAC3, HDAC1 | ATAD2 1406/4885BRD4 17/4885LMNA 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.